Antibiotic Resistance Market - By Drug Class (Cephalosporins, Combination Therapies, Tetracyclines, Lipoglycopeptides, Oxazolidinones, Others), By Disease (Complicated Urinary Tract Infection, Blood Stream Infections, Complicated Intra-Abdominal Infections, Clostridium Difficile Infections, Acute Bacterial Skin and Skin Structure Infections, Acute Bacterial Skin and Skin Structure Infections, Hospital-Acquired Bacterial Pneumonia/Ventilator, Community-Acquired Bacterial Pneumonia), By Pathogen (Staphylococcus Aureus, Streptococcus Pneumoniae, Acinetobacter, Enterococcus, Hemophilus Influenzae, Pseudomonas Aeruginosa, Clostridium Difficile, Pneumoniae, Campylobacter), By End User (Hospitals and Clinics, Research Organizations), By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 189
Status: Published
Report Code: ARI100382
Antimicrobial substances used to combat bacterial infection are termed as antibiotics. They are also used to heal a number of medical conditions like stroke, sinus, urinary tract infections, ear infections, pneumonia, skin infections, and other diseases. The classification of antibiotics is based on chemical structures, activity spectrum and action method. The capacity to withstand the infection is known as resistance to antibiotics. Worldwide, this is expected to be a key issue, leading to full-fledged emergence of the global antibiotic resistance market.
Rising antibiotic drug resistance infections is expected to drive the growth of the market. For instance, each year in the US, at least 2.8 million people get an antibiotic-resistant infection, and more than 35,000 people die. Rise in incidence of chronic and infectious disease is expected to drive the growth of the market. For instance, more than 17 million people were affected by contagious diseases globally. An increase in clinical developments of antibiotic resistance is expected to drive the growth of the market. For instance, as of June 2019, approximately 42 new antibiotic resistance with the potential to treat severe bacterial infections are in clinical development. Rise in global initiatives to control drug-resistance.
High medical costs. The cost of health care for patients suffering from resistant infections is higher than care for patients suffering from non-resistant infections due to the extended duration of illness, and increased usage of expensive drugs.
Pharmaceutical companies, such as GlaxoSmithKline, Johnson & Johnson, Novartis, and Sanofi, are at the forefront of the global pharmaceutical industry but are less actively involved in clinical development of antibiotics
Analyst Commentary
There is an extensive occurrence of antibiotic resistance among 5,00,000 people with suspected bacterial infections across 22 countries in the antibiotic resistance marker. As a result, increasing the occurrence of antibiotic resistance would drive the demand for the global antibiotic resistance market.
Antibiotic resistance occurs naturally, but the misuse of antibiotics in humans would increase the growth of antimicrobial resistance. Bacteria become resistant to the antibiotics that are designed to kill them. Increasing antibiotic-resistant infections and emergence of multi-drug resistant pathogens will enhance the growth of antibiotic resistance market. For instance, in 2016, approximately 49,000 people developed multi-drug resistant TB globally, and drug resistance is complicating the fight against HIV as well as malaria
The Antibiotic Resistance market is expected to witness significant traction over the next decade due to the rising prevalence of bacterial infection. According to the World Health Organization, about 70% of the world population has a bacterial infection once in their lifetime. Biotechnology companies Melinta Therapeutics, Achaogen, and Nabriva Therapeutics are solely focusing to develop the therapies for the antibiotic resistance infection. While major pharmaceutical companies are not focusing to develop the therapies for the antibiotic resistance infection. Among all end user, hospital pharmacies is the leading segment in the of revenue share for global antibiotics resistance which is then followed by the retail pharmacies. While online pharmacies are the fasted growing segment by end user for antibiotic resistance market over the forecast period.
Segmentation
Antibiotic resistance market is segmented into five categories which are further segmented into subcategories. First category is by drug class and the subcategory includes Cephalosporins, Combination Therapies, Tetracyclines, Lipoglycopeptides, Oxazolidinones, Others. Second category is by disease and its subcategory includes Complicated Urinary Tract Infection, Blood Stream Infections, Complicated Intra-Abdominal Infections, Clostridium Difficile Infections, Acute Bacterial Skin and Skin Structure Infections, Acute Bacterial Skin and Skin Structure Infections, Hospital-Acquired Bacterial Pneumonia/Ventilator, Community-Acquired Bacterial Pneumonia. Third category is by pathogen and the subcategories include Staphylococcus Aureus, Streptococcus Pneumoniae, Acinetobacter, Enterococcus, Hemophilus Influenzae, Pseudomonas Aeruginosa, Clostridium Difficile, Pneumoniae, Campylobacter. Fourth category is by end user and the sub categories are hospitals and clinics, research organizations. Fifth and last category is by region and the sub categories are Americas, Europe, Asia-Pacific, Middle East & Africa.
Regional analysis
North America was the largest region in terms of revenue in 2017. Numerous drug launches in the market and high treatment cost are supplementing the growth of the regional market. The U.S. will be a key revenue contributor in the region during the forecast period as guidelines, such as those defined by IDSA for the treatment of CDI, are promoting the use of novel therapies.
Europe was the second largest regional market in the global arena in 2017, supported largely by growing number of antibiotic-resistant infections. Among the OECD countries, Greece, Italy, and Portugal were ranked as the top 3 consumers of antibiotics in the world, contributing to increased antibiotic resistance in the region.
North America was the largest region in terms of revenue in 2017. Numerous drugs launch in the market and high treatment cost are supplementing the growth of the regional market. The U.S. will be a key revenue contributor in the region during the forecast period as guidelines, such as those defined by IDSA for the treatment of CDI, are promoting the use of novel therapies.
Europe was the second largest regional market in the global arena in 2017, supported largely by growing number of antibiotic-resistant infections. Among the OECD countries, Greece, Italy, and Portugal were ranked as the top 3 consumers of antibiotics in the world, contributing to increased antibiotic resistance in the region
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary data mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Global Antibiotic Resistance Market
Chapter 5. Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
5.1. Global Antibiotic Resistance Market Share, By Drug Class, 2015 - 2027 (USD Million)
5.1.1. Amino Acid
5.1.1.1. Market Size and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Antibiotics
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. Vitamins
5.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.4. Feed Acidifiers
5.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
6.1. Global Antibiotic Resistance Share, By Disease, 2015 - 2027 (USD Million)
6.1.1. Fish
6.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Mollusks
6.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Crustaceans
6.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.4. Others
6.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
7.1. Global Antibiotic Resistance Share, By Pathogen, 2015 - 2027 (USD Million)
7.1.1. Staphylococcus aureus
7.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.2. Streptococcus Pneumonia
7.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.3. Neisseria Gonorrhoeae
7.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.4. Enterococcus faecium
7.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.5. Escherichia coli
7.1.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.5.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.6. Klebsiella pneumonia
7.1.6.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.6.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.7. Shigella
7.1.7.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.7.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.8. Clostridium difficile
7.1.8.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.8.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 8. Global Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
8.1. Global Antibiotic Resistance Share, By Pathogen, 2015 - 2027 (USD Million)
8.1.1. Hospitals
8.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
8.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
8.1.2. Clinics
8.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
8.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 9. Global Antibiotic Resistance Market Overview, By Geography, 2015 – 2027 (USD Million)
9.1. Global Antibiotic Resistance Market Share, By Geography, 2015 - 2027 (USD Million)
9.1.1. Market Size and projections, by Countries, 2015 – 2027 (USD Million)
9.1.2. Market Share and CAGR Comparison, by Countries, 2019 (%)
Chapter 10. North America Global Antibiotic Resistance Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. North America Global Antibiotic Resistance Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.2. North America Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.3. North America Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
10.1.4. North America Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
10.1.5. North America Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.6. North America Global Antibiotic Resistance Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.6.1. U.S. Global Antibiotic Resistance Market Overview, 2015 - 2027 (USD Million)
10.1.6.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.6.1.2. U.S. Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.6.1.3. U.S. Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
10.1.6.1.4. U.S. Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
10.1.6.1.5. U.S. Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.6.1.6.
10.1.6.2. Canada Global Antibiotic Resistance Market Overview, 2015 - 2027 (USD Million)
10.1.6.2.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.6.2.2. Canada Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.6.2.3. Canada Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
10.1.6.2.4. Canada Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
10.1.6.2.5. Canada Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.6.2.6.
10.1.6.3. Mexico Global Antibiotic Resistance Market Overview, 2015 - 2027 (USD Million)
10.1.6.3.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.6.3.2. Mexico Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.6.3.3. Mexico Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
10.1.6.3.4. Mexico Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
10.1.6.3.5. Mexico Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
Chapter 11. Europe Global Antibiotic Resistance Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Europe Global Antibiotic Resistance Market Overview, 2015 – 2027 (USD Million)
11.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.2. Europe Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.3. Europe Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
11.1.4. Europe Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
11.1.5. Europe Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.6. Europe Global Antibiotic Resistance Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.6.1. Germany
11.1.6.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.6.1.2. Germany Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.6.1.3. Germany Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
11.1.6.1.4. Germany Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
11.1.6.1.5. Germany Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.6.2. France
11.1.6.2.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.6.2.2. France Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.6.2.3. France Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
11.1.6.2.4. France Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
11.1.6.2.5. France Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.6.3. UK
11.1.6.3.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.6.3.2. UK Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.6.3.3. UK Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
11.1.6.3.4. UK Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
11.1.6.3.5. UK Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.6.4. Italy
11.1.6.4.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.6.4.2. Italy Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.6.4.3. Italy Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
11.1.6.4.4. Italy Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
11.1.6.4.5. Italy Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.6.5. Spain
11.1.6.5.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.6.5.2. Spain Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.6.5.3. Spain Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
11.1.6.5.4. Spain Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
11.1.6.5.5. Spain Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.6.6. Rest of Europe
11.1.6.6.1. Market size and projections, 2015 – 2025
11.1.6.6.2. Rest of Europe Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.6.6.3. Rest of Europe Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
11.1.6.6.4. Rest of Europe Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
11.1.6.6.5. Rest of Europe Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
Chapter 12. Asia Pacific Global Antibiotic Resistance Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. Asia Pacific Antibiotic Resistance Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.2. Asia Pacific Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.3. Asia Pacific Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
12.1.4. Asia Pacific Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
12.1.5. Asia Pacific Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.6. Asia Pacific Global Antibiotic Resistance Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1.6.1. India
12.1.6.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.1.2. India Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.6.1.3. India Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
12.1.6.1.4. India Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
12.1.6.1.5. India Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.6.2. China
12.1.6.2.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.2.2. China Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.6.2.3. China Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
12.1.6.2.4. China Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
12.1.6.2.5. China Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.6.3. Japan
12.1.6.3.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.3.2. Japan Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.6.3.3. Japan Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
12.1.6.3.4. Japan Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
12.1.6.3.5. Japan Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.6.4. South Korea
12.1.6.4.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.4.2. South Korea Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.6.4.3. South Korea Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
12.1.6.4.4. South Korea Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
12.1.6.4.5. South Korea Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.6.5. Rest of Asia Pacific
12.1.6.5.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.5.2. Rest of Asia Pacific Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.6.5.3. Rest of Asia Pacific Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
12.1.6.5.4. Rest of Asia Pacific Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
12.1.6.5.5. Rest of Asia Pacific Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
Chapter 13. Middle East & Africa Global Antibiotic Resistance Market Overview, By Countries, 2015 - 2027 (USD Million)
13.1. Middle East & Africa Global Antibiotic Resistance Market Overview, 2015 - 2027 (USD Million)
13.1.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.2. Middle East & Africa Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
13.1.3. Middle East & Africa Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
13.1.4. Middle East & Africa Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
13.1.5. Middle East & Africa Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
13.1.6. Middle East & Africa Global Antibiotic Resistance Market Overview, By Countries, 2015 - 2027 (USD Million)
13.1.6.1. GCC
13.1.6.1.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.6.1.2. GCC Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
13.1.6.1.3. GCC Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
13.1.6.1.4. GCC Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
13.1.6.1.5. GCC Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
13.1.6.2. South Africa
13.1.6.2.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.6.2.2. South Africa Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
13.1.6.2.3. South Africa Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
13.1.6.2.4. South Africa Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
13.1.6.2.5. South Africa Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
13.1.6.3. Rest of Middle East & Africa
13.1.6.3.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.6.3.2. Rest of Middle East & Africa Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
13.1.6.3.3. Rest of Middle East & Africa Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
13.1.6.3.4. Rest of Middle East & Africa Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
13.1.6.3.5. Rest of Middle East & Africa Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
Chapter 14. South America Global Antibiotic Resistance Market Overview, By Countries, 2015 - 2027 (USD Million)
14.1. South America Global Antibiotic Resistance Market Overview, 2015 - 2027 (USD Million)
14.1.1. Market size and projections, 2015 - 2027 (USD Million)
14.1.2. South America Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
14.1.3. South America Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
14.1.4. South America Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
14.1.5. South America Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
14.1.6. South America Global Antibiotic Resistance Market Overview, By Countries, 2015- 2026 (USD Million)
14.1.6.1. Brazil
14.1.6.1.1. Market size and projections, 2015 - 2027 (USD Million)
14.1.6.1.2. Brazil Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
14.1.6.1.3. Brazil Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
14.1.6.1.4. Brazil Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
14.1.6.1.5. Brazil Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
14.1.6.2. Argentina
14.1.6.2.1. Market size and projections, 2015 - 2027 (USD Million)
14.1.6.2.2. Argentina Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
14.1.6.2.3. Argentina Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
14.1.6.2.4. Argentina Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
14.1.6.2.5. Argentina Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
14.1.6.3. Rest of South America
14.1.6.3.1. Market size and projections, 2015 – 2026
14.1.6.3.2. Rest of South America Global Antibiotic Resistance Market Overview, By Drug Class, 2015 - 2027 (USD Million)
14.1.6.3.3. Rest of South America Antibiotic Resistance Market Overview, By Disease, 2015 - 2027 (USD Million)
14.1.6.3.4. Rest of South America Antibiotic Resistance Market Overview, By Pathogen, 2015 - 2027 (USD Million)
14.1.6.3.5. Rest of South America Antibiotic Resistance Market Overview, By End User, 2015 - 2027 (USD Million)
Chapter 15. Competitive Landscape
15.1. Competitive environment, 2020
15.2. Strategic framework
15.2.1. Partnership/agreement
15.2.2. Expansion
15.2.3. Mergers & Acquisitions
15.2.4. New Drug Class development
Chapter 16. Key Application Analysis
16.1. GlaxoSmithKline
16.1.1. Company overview
16.1.2. Financial performance
16.1.3. Drug Class Benchmarking
16.1.4. Recent initiatives
16.1.5. SWOT analysis
16.2. Johnson & Johnson
16.2.1. Company overview
16.2.2. Financial performance
16.2.3. Drug Class Benchmarking
16.2.4. Recent initiatives
16.2.5. SWOT analysis
16.3. Johnson & Johnson
16.4. Novartis.
16.5. Sanofi
Chapter 17. Global Antibiotic Resistance Market Cost Analysis
17.1. Global Antibiotic Resistance Market Key Raw End Users Analysis
17.1.1. Key Raw End Users
17.1.2. Price Trend of Key Raw End Users
17.1.3. Key Suppliers of Raw End Users
17.1.4. Market Concentration Rate of Raw End Users
17.2. Proportion of Wing Cost Structure
17.2.1. Raw End Users
17.2.2. Labor Cost
17.2.3. Wing Expenses
17.3. Wing Process Analysis of Unsaturated Polyester Resin (UPR) for Electric ATV
Chapter 18. Chain, Sourcing Strategy and Downstream Buyers
18.1. Global Antibiotic Resistance Market Chain Analysis
18.2. Upstream Raw End Users Sourcing
18.3. Raw End Users Sources of Global Antibiotic Resistance Market Major Manufacturers in 2019
18.4. Downstream Buyers
Chapter 19. Marketing Strategy Analysis, Distributors/Traders
19.1. Marketing Channel
19.1.1. Direct Marketing
19.1.2. Indirect Marketing
19.1.3. Marketing Channel Development Trend
19.2. Market Positioning
19.2.1. Pricing Strategy
19.2.2. Brand Strategy
19.2.3. Target Amino Acidal Damage
19.3. Distributors/Traders List
Chapter 20. Market Effect Factors Analysis
20.1. Drug Class Progress/Risk
20.1.1. Substitutes Threat
20.1.2. Drug Class Progress in Related Industry
20.2. Oncology Needs/Customer Preference Change
20.3. Economic/Political Environmental Change
Chapter 21. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Antibiotic Resistance Market share, by Drug Class, 2020 & 2027 (%)
10. Global Antibiotic Resistance Market share, by Drug Class 2020 & 2027 (USD Million)
11. Global Antibiotic Resistance Market share, by Amino Acid, by Drug Class, 2020 & 2027 (USD Million)
12. Global Antibiotic Resistance Market share, by Antibiotics, by Drug Class, 2020 & 2027 (USD Million)
13. Global Antibiotic Resistance Market share, by Vitamins, by Drug Class, 2020 & 2027 (USD Million)
14. Global Antibiotic Resistance Market share, by Feed Acidifiers, by Drug Class, 2020 & 2027 (USD Million)
15. Global Antibiotic Resistance Market share, By Disease, 2020 & 2027 (%)
16. Global Antibiotic Resistance Market share, by Fish, By Disease, 2020 & 2027 (USD Million)
17. Global Antibiotic Resistance Market share, by Mollusks, By Disease, 2020 & 2027 (USD Million)
18. Global Antibiotic Resistance Market share, by Crustaceans, By Disease, 2020 & 2027 (USD Million)
19. Global Antibiotic Resistance Market share, by Others, By Disease, 2020 & 2027 (USD Million)
20. Global Antibiotic Resistance Market share, By Pathogen, 2020 & 2027 (%)
21. Global Antibiotic Resistance Market share, by Staphylococcus Aureus, By Pathogen, 2020 & 2027 (USD Million)
22. Global Antibiotic Resistance Market share, by Streptococcus Pneumonia, By Pathogen, 2020 & 2027 (USD Million)
23. Global Antibiotic Resistance Market share, by Neisseria Gonorrhoeae, By Pathogen, 2020 & 2027 (USD Million)
24. Global Antibiotic Resistance Market share, by Enterococcus faecium, By Pathogen, 2020 & 2027 (USD Million)
25. Global Antibiotic Resistance Market share, By End User, 2020 & 2027 (%)
26. Global Antibiotic Resistance Market share, by Hospitals, By End User, 2020 & 2027 (USD Million)
27. Global Antibiotic Resistance Market share, by Clinics ATV, By End User, 2020 & 2027 (USD Million)
28. Global Antibiotic Resistance Market share, by region, 2020 - 2027(%)
29. Global Antibiotic Resistance Market share, by region, 2019 - 2027(USD Million)
30. North America Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
31. North America Global Antibiotic Resistance Market share, by Countries, 2020 & 2027 (%)
32. U.S. Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
33. Canada Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
34. Europe Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
35. Europe Global Antibiotic Resistance Market share, by Countries, 2020 & 2027 (%)
36. Spain Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
37. UK Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
38. Italy Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
39. Germany Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
40. France Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
41. Rest of Europe Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
42. Asia-Pacific Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
43. Asia-Pacific Global Antibiotic Resistance Market share, by Countries, 2020 & 2027 (%)
44. China Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
45. India Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
46. Australia Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
47. Japan Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
48. Rest of Asia-Pacific Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
49. Middle East & Africa Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
50. Middle East & Africa Global Antibiotic Resistance Market share, by Countries, 2020 & 2027 (%)
51. GCC Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
52. South Africa Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
53. Rest of Middle East & Africa Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
54. South America Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
55. Brazil Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
56. Mexico Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
57. Argentina Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
58. Rest Of South America Global Antibiotic Resistance Market, 2020 - 2027(USD Million)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Antibiotic Resistance Market, 2020-2027 (USD Million)
4. Antibiotic Resistance requirement, by country, 2020-2027, (USD Million)
5. North America Antibiotic Resistance Market, by Drug Class, 2020-2027 (USD Million)
6. North America Antibiotic Resistance Market, By Disease, 2020-2027 (USD Million)
7. North America Antibiotic Resistance Market, By Pathogen, 2020-2027 (USD Million)
8. North America Antibiotic Resistance Market, By End User, 2020-2027 (USD Million)
9. Europe Antibiotic Resistance Market, by Drug Class, 2020-2027 (USD Million)
10. Europe Antibiotic Resistance Market, By Disease, 2020-2027 (USD Million)
11. Europe Antibiotic Resistance Market, By Pathogen, 2020-2027 (USD Million)
12. Europe Antibiotic Resistance Market, By End User, 2020-2027 (USD Million)
13. Asia Pacific Antibiotic Resistance Market, by Drug Class, 2020-2027 (USD Million)
14. Asia Pacific Antibiotic Resistance Market, By Disease, 2020-2027 (USD Million)
15. Asia Pacific Antibiotic Resistance Market, By Pathogen, 2020-2027 (USD Million)
16. Asia Pacific Antibiotic Resistance Market, By End User, 2020-2027 (USD Million)
17. Middle East & Africa Global Antibiotic Resistance Market, by Drug Class, 2020-2027 (USD Million)
18. Middle East & Africa Antibiotic Resistance Market, By Disease, 2020-2027 (USD Million)
19. Middle East & Africa Cabin Interiors Market, By Pathogen, 2020-2027 (USD Million)
20. Middle East & Africa Antibiotic Resistance Market, By End User, 2020-2027 (USD Million)
21. South America Antibiotic Resistance Market, by Drug Class, 2020-2027 (USD Million)
22. South America Antibiotic Resistance Market, By Disease, 2020-2027 (USD Million)
23. South America Antibiotic Resistance Market, By Pathogen, 2020-2027 (USD Million)
24. South America Antibiotic Resistance Market, By End User, 2020-2027 (USD Million)
25. Global Antibiotic Resistance Market, Company Market Share, 2018 (%)
26. IQAir: Product Benchmarking
27. IQAir: Financial Performance
28. Johnson & Johnson: Product Benchmarking
29. Johnson & Johnson: Financial Performance
30. Johnson & Johnson: Product Benchmarking
31. Johnson & Johnson: Financial Performance
32. Novartis: Product Benchmarking
33. Novartis: Financial Performance
34. Sanofi: Product Benchmarking
35. Sanofi: Financial Performance
The Leading Key Players in Antibiotic Resistance Market
GlaxoSmithKline
Johnson & Johnson
Novartis
Sanofi
